Association of MC1R Variants and Risk of Melanoma in Melanoma-Prone Families with CDKN2A Mutations

  1. Alisa M. Goldstein1,
  2. Maria Teresa Landi1,
  3. Shirley Tsang2,
  4. Mary C. Fraser1,
  5. David J. Munroe2 and
  6. Margaret A. Tucker1
  1. 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda and 2Laboratory of Molecular Technology, National Cancer Institute at Frederick, Science Applications International Corporation-Frederick, Frederick, NIH, Department of Health and Human Services, Maryland
  1. Requests for reprints:
    Alisa M. Goldstein, Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Executive Plaza South, Room 7004, 6120 Executive Boulevard, MSC 7236 Bethesda, MD 20892-7236. Phone: 301-496-4375; Fax: 301-402-4489. E-mail: goldstea{at}exchange.nih.gov

Abstract

Major risk factors for melanoma include many nevi, especially dysplastic nevi, fair pigmentation, freckling, poor tanning ability, and germ line mutations in the CDKN2A, CDK4, or MC1R genes. We evaluated the relationship between MC1R and melanoma risk in CDKN2A melanoma-prone families with extensive clinical and epidemiologic data. We studied 395 subjects from 16 American CDKN2A families. Major melanoma risk factors were assessed by clinical examination or questionnaire; MC1R was sequenced. Odds ratios were estimated by unconditional and conditional logistic regression models. We examined the distribution of MC1R variants and median ages at melanoma diagnosis in multiple primary melanoma (MPM) and single primary melanoma (SPM) patients. Presence of multiple MC1R variants was significantly associated with melanoma, even after adjustment for major melanoma risk factors. All 40 MPM patients had at least one MC1R variant; 65% of MPM patients versus only 17% of SPM patients had at least two MC1R variants (P < 0.0001). For all 69 melanoma patients combined, as well as the 40 MPM patients, there was a statistically significant decrease in median age at diagnosis as numbers of MC1R variants increased (P = 0.010 and P = 0.008, respectively). In contrast, no significant reduction in age at melanoma diagnosis was observed for SPM patients (P = 0.91). The current study suggests that the presence of multiple MC1R variants is associated with the development of multiple melanoma tumors in patients with CDKN2A mutations. Additional studies are needed to confirm these findings and to explore the mechanisms that may contribute to this relationship.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted July 5, 2005.
    • Received May 3, 2005.
    • Revision received June 21, 2005.
« Previous | Next Article »Table of Contents